Lollylab detects acetaminophen in six adults in under two minutes

By Amara Osei

USC researchers’ Lollylab prototype detected acetaminophen in saliva from six adults in less than two minutes, according to the American Chemical Society, but the study did not include children.

The result supports a collection-and-assay proof of concept for a drug associated with accidental pediatric dosing errors. It does not yet establish clinical accuracy, safe exposure thresholds or a route into routine checkups.

The broader premise rests on saliva’s established diagnostic value; laboratories can use it to detect signs of heart failure, according to the account. The source gives no performance data for that precedent, so it cannot transfer validation to Lollylab.

How does the lollipop collect a sample?

USC researchers developed Lollylab to make saliva collection more acceptable to children. The American Chemical Society account says the device “packs a miniature laboratory inside,” although that description captures the function rather than the technology’s maturity: it remains an experimental prototype.

Lollylab consists of two plastic pieces with stems and rounded tops that snap together. Small holes in the rounded head admit saliva, which travels down a glass-fiber stem lined with paper to a sensor at the bottom.

Saliva reaches the sensor in about 60 seconds, and the assay requires approximately 0.3 milliliters, roughly six drops. The rounded top carries a red, peach-flavored candy shell, so users collect the sample by licking a familiar object rather than using a conventional swab.

What does the electrode actually detect?

The prototype targets acetaminophen, a common ingredient in over-the-counter painkillers and cold and flu medicines. Although available without prescription, excessive acetaminophen can cause serious effects, including liver damage, and accidental dosing mistakes are especially hazardous for children.

Researchers selected acetaminophen because its concentration in saliva can reflect its blood concentration quite precisely, according to the account. That relationship could support drug monitoring without a blood draw, but the six-adult experiment reported neither blood values nor a calibrated relationship between the two concentrations.

When acetaminophen-containing saliva reaches an electrode made from laser-induced graphene, a chemical reaction produces an electrical signal. The prototype measures that signal to identify the drug; the report does not specify the readout device or whether the output becomes a binary result, a concentration estimate or a clinician-ready trace.

The source says laser-induced graphene is already widely used in wearable health monitors, environmental sensors and water purification systems. That indicates familiarity with the material, not Lollylab’s sensitivity, manufacturing yield, shelf life or cost per disposable, none of which the report quantifies.

Is the evidence strong enough for pediatric use?

The researchers tested both artificial saliva and real human saliva. In the human component, six adults took acetaminophen and then provided samples by licking Lollylab; the device detected the drug in less than two minutes.

Participants reported that collection was “much easier and more comfortable” than collection with conventional swabs. That is a favorable usability signal, although the report provides no questionnaire, rating scale, comparator protocol or demographic breakdown with which to assess the claim.

Six adults cannot establish performance in children, whose saliva volume, medication exposure and ability to follow collection instructions may differ. The account also omits artificial-sample numbers, blind controls, acetaminophen dose levels, detection limits, false-positive rates, adverse events and independent replication.

For deployment, the source does not explain how a result reaches a clinician or another decision-maker. Lollylab currently operates as a sample collector and sensor rather than a demonstrated end-to-end diagnostic with validated interpretation, software and a documented manufacturing process.

The account names USC but does not identify the investigators, publication date, journal, funding source, conflicts of interest, patent position or licensing activity. A research manager cannot assess reproducibility, sponsor incentives or freedom to operate from the information provided.

What does the team plan to test next?

USC researchers plan larger studies and adaptation of the technology to other substances in saliva. The report provides no enrollment target, analyte list, validation standard, development timeline or commercial partner, leaving those plans as a research direction rather than a forecast of an approved test.

For R&D managers, the immediate decisions concern reproducibility, comparability and unit economics. Teams would need to quantify accuracy across acetaminophen doses, compare the six-drop method with standard swabs and laboratory assays, and establish how candy coatings, paper liners and graphene electrodes change consistency, contamination risk and production cost.

Clinical studies would also need to test the age group that motivates the design. Pediatric enrollment, caregiver workflow, result turnaround, safe handling and an interpretation protocol would carry more decision weight than the prototype’s appealing format.

The measured milestone is narrow but concrete: six adults, approximately 0.3 milliliters of saliva, a 60-second delivery path and detection in under two minutes. The next milestone must be equally concrete—larger, independently replicated studies in children with reported accuracy limits—before Lollylab can support routine clinical decisions.